Wednesday, December 10, 2025 7:11:19 AM
Excuse me for interjecting myself in here, but I have to say, I couldn't care less what joe retail says about value, as long as their focus sidesteps or demonstrates a full academic understanding of what they own. It's understanding the significance of how meticulously the company has carved out DATA.ownership, not only of its core platform, but also in combination with existing blockbuster modalities, which forces BP to come to NWBO, whether BP likes the deal or not. You're absolutely right, we see BP's spending top dollar on preliminary mouse models, buying up immunologic treatment components, not standalone, which only deepens their interdependence on a mature DCVax platform. What does NWBO have to show for two decades of development time, DATA. Setting aside future trials, NWBO hasn't stopped accruing real-life treatment data for the last several years through the UK specials program. That data sits behind a firewall. That's a monsterous blindspot for shorts. How many pre revenue biotechs have that luxury? After all, it's an ongoing LIVING TRIAL. The longer it goes the greater the statistical power generated. Andrew illlustrates the elegance of platform's progression, which joe retail, especially shorts are incapable, nor paid to want to understand. If they were, they wouldn't spend their entire lives as anonymous cartoon characters, at best, posting juvenile b.s. 24/7. "SP", "dilusion" "grift" "nobody cares"... etc. are SyOp key words to distract attention away from the intrinsic value the company has built. I invested in this company ahead of it going commercial, and tracking completed milestones towards that eventuality. The rest is noise.
Potential CURE for cancer - DCVax could well be the biggest medical breakthrough - EVER
Recent NWBO News
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/26/2025 05:15:34 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/31/2025 09:23:24 PM
Eco Science Solutions Integrates IDScan.net's DIVE Into Herbo Pay to Power Identity Verification, Compliance, and Fraud Prevention • ESSI • Mar 27, 2026 12:01 PM
The Crypto Company Acquires FRAME Blockchain's Technology, An "Interstate Highway" Liquidity Layer for Crypto Commerce • CRCW • Mar 26, 2026 12:28 PM
Resilient Energy Inc. Enters LOI Negtiations for Second Acquisition; First Acquisition Nears Closing • RENI • Mar 26, 2026 10:30 AM
Alliance Creative Group (ACGX) Releases 2025 Annual Financial and Disclosure Report • ACGX • Mar 26, 2026 8:30 AM
Isiah Enterprises Activates Scalable Materials Platform Targeting $900B+ Global Market Opportunity; Initiates Strategic Partner Alignment Phase • OWPC • Mar 25, 2026 9:07 AM
ECGI Signs Definitive $25 Million Agreement to Acquire RezyFi • ECGI • Mar 24, 2026 8:30 AM
